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Role of Biomarkers in Juvenile Idiopathic Arthritis
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Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
The aim of this review was to identify the utility of biomarkers used in the diagnosis and the monitoring and treatment of Juvenile 
idiopathic arthritis (JIA). JIA is a heterogeneous group of diseases characterized by arthritis of unknown etiology that lasts for 
at least 6 weeks, with onset before the age of 16 years. Unlike adult rheumatoid arthritis, JIA is a heterogeneous arthritis with 
different subtypes. The diagnosis of JIA is based on clinical evaluation and often involves ruling out other causes of arthritis. 
Many biomarkers have been studied or are under development to define the classifications of JIA, assess disease activity, predict 
disease course, treatment response, or the risk of relapse. The diagnostic and prognostic use of biomarkers in JIA could be ap-
plied differently depending on diverse subtypes or individuals. To obtain the best clinical outcomes in JIA, it is important to un-
derstand the pathophysiology of each JIA subtype and to select and use appropriate biomarkers. (J Rheum Dis 2020;27:233-240)
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is the most common 
chronic rheumatic disease in childhood, and may result in 
significant morbidity [1]. JIA refers to the onset of arthri-
tis with no defined cause before 16 years of age and in-
cludes symptoms that persist for at least 6 weeks [2]. The 
diagnosis of JIA can be difficult because JIA is a heteroge-
neous group of conditions that manifests inflammatory 
arthritis without a definite test to confirm the diagnosis. 
Furthermore, there are many diseases that can mimic JIA 
[3]. The current classification categories created for JIA 
are primarily for research purposes and are not intended 
for use as diagnostic criteria in the clinical setting [4]. 
Therefore, JIA is diagnosed clinically and is based on a 
combination of presenting signs and symptoms, blood 
tests, and if necessary, medical imaging. A number of bio-
markers have been used or are under development to as-
sist with the diagnosis of JIA. These biomarkers not only 
help to predict the course of the disease but are also use-
ful to predict the patient’s response to treatment and 
relapse.
This review therefore sought to identify the utility of bi-
omarkers used in the diagnosis and treatment monitoring 
of JIA.
MAIN SUBJECTS
The utility of biomarkers used in JIA include classifying 
the JIA subtypes, evaluating disease activity, predicting 
the disease course, treatment response, or the risk of 
relapse. Table 1 summarizes the biomarkers (existing and 
promising) that can be used in JIA. 
Consideration for new classification of JIA
Several classification systems for chronic arthritis in 
childhood have been proposed over the past few decades 
[5]. The older terms “juvenile rheumatoid arthritis,” 
commonly used by the American College of Rheumatology 
(ACR), and “juvenile chronic arthritis” by the European 
League Against Rheumatism, were replaced by the term 
“juvenile idiopathic arthritis” (JIA) at the Pediatric 
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Table 1. Biomarkers that can be used in juvenile idiopathic 
arthritis
Utility Biomarkers







in systemic JIA (S100 
proteins, IL-18)










Biomarkers predicting MAS 
in systemic JIA (ferritin, 
platelet count, AST, 
triglycerides, fibrinogen, 
soluble CD25, soluble 
CD163 etc.)
Biomarkers that predict 
response to therapy and relapse
S100 proteins
IL-18
JIA: juvenile idiopathic arthritis, RF: rheumatoid factor, HLA: 
human leukocyte antigen, ANA: antinuclear antibody, CCP: 
cyclic citrullinatedpeptide, IL: interleukin, CRP: C-reactive 
protein, ESR: erythrocyte sedimentation rate, MMP-3: matrix 
metalloproteinase-3, AST; aspartate aminotransferase, MAS: 
macrophage activation syndrome. 
Standing Committee of the International League of 
Associations for Rheumatology (ILAR) in 1993 [6,7]. In 
the current classification system established by ILAR, JIA 
is further categorized into 7 distinct subtypes, based on 
their presentation within the first 6 months (Table 2). 
Most pediatric rheumatologists agree that the ILAR cri-
teria are require revision for several reasons: the criteria 
have been established for more than 20 years, and the 
number of affected joints or the presence of psoriasis does 
not reflect a homogeneous immune pathogenesis [8,9]. 
Although there is controversy regarding the method em-
ployed to change the criteria, a consensus conference led 
by the Pediatric Rheumatology International Trials 
Organization (PRINTO) recently proposed a new classi-
fication system that is in the process of validation (Table 
3) [10]. 
Biomarkers used to define the JIA subtypes
Biomarkers that are useful to classify the subtypes of JIA 
include rheumatoid factor (RF), human leukocyte anti-
gen (HLA)-B27, antinuclear antibody (ANA), and an-
ti-cyclic citrullinated peptide (CCP) antibodies.
RFs are antibodies directed against the Fc fragment of 
immunoglobulin G (IgG). They are heterogeneous and 
usually composed of IgM; therefore, most assays detect 
only IgM [11]. RFs cannot be used to diagnose JIA be-
cause IgM RFs are rarely found in children younger than 
7 years of age, and can be detected not only in children 
with other autoimmune diseases but also in healthy 
children. Nevertheless, RFs are an important component 
of both the ILAR classification criteria and the newly pro-
posed PRINTO criteria (Tables 2 and 3). RFs are most 
commonly detected in children with a later age at JIA on-
set and in those with polyarticular involvement [12]. In 
the PRINTO classification, RF-positive JIA is considered 
to be the pediatric counterpart of RF-positive rheumatoid 
arthritis (RA) in adults [10].
HLA-B27 is a class I surface antigen encoded by the B lo-
cus in the major histocompatibility complex, and has an 
affinity for antigenic peptides and presents them to cyto-
toxic T-lymphocytes [13]. The presence of HLA-B27 is an 
important part of the inclusion criteria used in the defi-
nition of enthesitis-related arthritis (ERA) based on the 
ILRA criteria or according to the definition of the en-
thesitis/spondylitis-related JIA provided by PRINTO 
(Tables 2 and 3). Approximately 60%∼80% of children 
with ERA represent positive for HLA-B27 [12]. Although 
HLA-B27 is frequently present in these children, the 
presence or absence of HAL-B27 cannot be relied upon to 
confirm or exclude the diagnosis of JIA. The allele is an in-
dicator of risk rather than a diagnostic test. HLA-B27 also 
has a strong association with ankylosing spondylitis (AS), 
which is notable considering that ERA is thought to be 
the pediatric counterpart of adult AS.
ANAs are antibodies that can be directed against cellular 
antigens and are detected predominantly in the nucleus 
and in other cellular components. ANAs may be found in 
5%∼18% of healthy children who do not show evidence 
of arthritis [14], which limits their use for diagnostic 
testing. However, ANAs are most frequently found in 
65%∼85% of young girls with oligoarthritis and uveitis 
[15,16]. These findings suggest that ANA positivity may 
represent a unique condition in JIA. Therefore, the 
PRINTO proposed a new diagnostic criterion called ear-
ly-onset ANA-positive JIA that was not addressed in the 
ILAR criteria (Table 3) [10]. This subtype exists only in 
JIA and does not have a matching form in adults. 
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Table 2. International League of Associations for Rheumatology (ILAR) classification for juvenile idiopathic arthritis
Categories Criteria
1. Systemic arthritis • Fever of at least 2 weeks’ duration and arthritis in ≥1 joint
• Plus one or more of the following:
      Erythematous rash
      Lymphadenopathy
      Serositis
      Hepatomegaly and/or splenomegaly
• Exclusions: a, b, c, d
2. Oligoarthritis • Arthritis affecting ≤4 joints during the first 6 months of disease
There are 2 subcategories:
      Persistent: affect 4 or fewer joints throughout the disease course
      Extended: affect more than 4 joints after the first 6 months of disease
• Exclusions: a, b, c, d, e
3. Polyarthritis RF-negative • Arthritis affecting ≥5 joints during the first 6 months of disease
• Test for RF is negative
• Exclusions: a, b, c, d, e
4. Polyarthritis RF-positive • Arthritis affecting ≥5 joints during the first 6 months of disease
• Two or more test for RF at least 3 month apart during the first 6 months of disease are positive
• Exclusions: a, b, c, e
5. Psoriatic arthritis • Arthritis and psoriasis, or arthritis and at least 2 of the following:
Dactylitis
Nail pitting or onycholysis
Psoriasis in a first-degree relative
• Exclusions: b, c, d, e
6. Enthesitis-related arthritis • Arthritis and enthesitis, or arthritis or enthesitis with at least 2 of following:
The presence of or a history of sacroiliac joint tenderness and/or inflammatory 
  lumbosacral pain
The presence of HLA-B27 antigen
Onset of arthritis in a male over 6 years of age
Acute (symptomatic) anterior uveitis
History of ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with inflammatory 
  bowel disease, Reiter’s syndrome, or acute anterior uveitis in a first-degree relative
• Exclusions: a, d, e
7. Undifferentiated arthritis • Arthritis that fulfills criteria in no category or in 2 or more of the above categories
RF: rheumatoid factor, HLA: human leukocyte antigen. One of the major aims of the ILAR classification is the mutual exclusivity 
of the subtypes. Therefore, the following list of possible exclusion for each category was defined; a) Psoriasis or a history ofpsoriasis
in the patient or first-degree relative; b) Arthritis in an HLA-B27-positive male beginning after the sixth birthday; c) Ankylosing 
spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel disease or acute anterior uveitis, or a history of one of 
these disorders in a first-degree relative; d) The presence of immunoglobulin M rheumatoid factor and at least two occasions at least 
3 months a part; e) The presence of systemic juvenile idiopathic arthritis in the patient.
Anti-CCP antibodies are a group of autoantibodies that 
are directed against peptides and proteins that are 
citrullinated. Although the major clinical relevance of an-
ti-CCP antibodies is their association with adult RA, they 
are also detected in children with JIA. In a study by Tebo 
et al. [17], anti-CCP antibodies were found in 73% of chil-
dren with RF-positive polyarticular JIA, 19% with ex-
tended oligoarticular JIA, 13% with systemic JIA, 8% with 
RF-negative polyarticular JIA, 4% with ERA or persistent 
oligoarticular JIA, and in 2% of controls. Although an-
ti-CCP antibodies have not yet been included in the ILAR 
classification criteria, they are included in the new 
PRINTO criteria, in which RF-positive JIA was defined as 
arthritis that persisted over 6 weeks, along with 2 positive 
tests for RF at least 3 months apart, or at least 1 positive 
test for anti-CCP antibodies (Table 3).
Among the JIA subtypes, systemic JIA is considered to 
be an autoinflammatory condition that is both clinically 
and immunologically distinct from the other categories of 
JIA and therefore requires different therapy. In addition, 
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Table 3. Pediatric Rheumatology International Trials Organization (PRINTO) classification for juvenile idiopathic arthritis
Categories Criteria
1. Systemic JIA • Fever of unknown origin that is documented to be daily for at least 3 consecutive days and
reoccurring over a duration of at least 2 weeks and
• Accompanied by 2 major criteria OR 1 major criterion and 2 minor criteria. Major criteria
are (1) evanescent erythematous rash; and (2) arthritis. Minor criteria are (1) generalized 
lymph node enlargement and/or hepatomegaly and/or splenomegaly; (2) serositis; (3) 
arthralgia lasting 2 weeks or longer (in the absence of arthritis); and (4) leukocytosis (≥
15,000/mm3) with neutrophilia
2. RF-positive JIA • Arthritis for ≥6 weeks, and
• Association with 2 positive tests for RF at least 3 months apart or at least 1 positive test for 
antibodies to cyclic citrullinated peptide
3. Enthesitis/spondylitis-related JIA • Peripheral arthritis and enthesitis, or
• Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on 
imaging, or
• Arthritis or enthesitisplus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory
back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and
(5) history of a spondyloarthritis in a first-degree relative
4. Early-onset ANA-positive JIA • Arthritis for ≥6 weeks, and
• Early-onset (≤6 years), and
• Presence of 2 positive ANA tests with a titer ≥1/160 (tested by immunofluorescence) at 
least 3 months apart
Exclusions are systemic JIA, RF-positive arthritis, and enthesitis/spondylitis-related JIA
5. Other JIA • Arthritis for ≥6 weeks
• Does not fit criteria for disorders 1 to 4
6. Unclassified JIA • Arthritis for ≥6 weeks
• Fits ＞1 disorder 1∼4
JIA: juvenile idiopathic arthritis, RF: rheumatoid factor, ANA: antinuclear antibody, HLA: human leukocyte antigen. 
children with this subtype are at risk of a severe, 
life-threatening complication called macrophage activa-
tion syndrome (MAS). In this unique type of JIA, the con-
centrations of S100 proteins such as S100A8–S100A9, 
S100A12, and interleukin (IL)-18 are increased in the 
plasma of children with systemic JIA [18]; therefore, 
these proteins may be supportive candidate biomarkers 
for the diagnosis of systemic JIA.
Biomarkers used to measure disease activity
The biomarkers most commonly used to assess disease 
activity in JIA are C-reactive protein (CRP) and eryth-
rocyte sedimentation rate (ESR). CRP is an acute phase 
protein of hepatic origin the expression of which in-
creases following IL-6 secretion by macrophages and T 
cells. CRP levels begin to increase within hours of the on-
set of inflammation, with levels peaking between 1 and 3 
days [14]. The plasma half-life of CRP is 19 hours, mak-
ing it a more sensitive and accurate reflection of the acute 
phase response than ESR [19]. In addition, CRP levels 
normalize more rapidly than ESR in response to therapy. 
However, CRP does not have sufficient specificity to dif-
ferentiate infectious from noninfectious inflammation in 
JIA. ESR is the rate at which red blood cells settle though 
plasma to form a sediment in whole blood in a stand-
ardized tube over a period of 1 hour. ESR is also a 
non-specific measure of inflammation that is included in 
both the Juvenile Arthritis Disease Activity Score 
(JADAS) and the core response variables identified by the 
ACR, which are the standardized and certified assess-
ment tools of JIA disease activity. The JADAS includes 4 
measures: physician global assessment of disease activity, 
parent/patient global assessment of well-being, active 
joint count, and ESR [20]. The ACR pediatric core criteria 
for JIA comprises 6 items: physician global assessment of 
disease activity, parent/patient global assessment of over-
all well-being, functional ability, number of joints with ac-
tive arthritis, number of joints with limited range of mo-
tion, and ESR [21]. 
Other candidate biomarkers that are useful to measure 
disease activity are the S100 proteins and matrix metal-
loproteinase 3 (MMP3). The S100 proteins are a class of 
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Table 4. Diagnostic criteria for macrophage activation syndrome
HLH-2004 diagnostic guidelines Classification criteria for MAS complicating systemic JIA
A. Molecular diagnosis Ferritin ＞684 ng/mL and any 2 of the following:
B. Diagnostic criteria    • Platelet count ≤181×109/L
    • Fever    • AST ＞48 U/L
    • Splenomegaly    • Triglycerides ＞156 mg/dL
    • Cytopenia (at least 2∼3 lineages: hemoglobin 
＜90 gm/L, platelets ＜100×109/L, neutrophils ＜1.0×109/L)
   • Fibrinogen ≤360 mg/dL
    • Hypertriglyceridemia and/or hypofibrinogenemia (triglycerides 
≥265 mg/dL, fibrinogen ≤1.5 g/L)
    • Hemophagocytosis BM, spleen, or lymph nodes
    • Low or absent NK cell activity
    • Ferritin ≥500 ng/mL
    • Soluble CD25 ≥2,400
The diagnosis of HLH can be established in presence of a molecular 
diagnosis consistent with HLH or by meeting 5 of 8 clinical and 
laboratory diagnostic criteria
A febrile patient with known or suspected systemic JIA is 
classified as having MAS if the above criteria are met
HLH: hemophagocytic lymphohistiocytosis, BM: bone marrow, MAS: macrophage activation syndrome, AST: aspartate 
aminotransferase, NK: natural killer cells.
pro-inflammatory calcium-binding proteins that are in-
volved in the regulation of calcium homeostasis, enzyme 
activities, energy metabolism, cell growth and differ-
entiation, and cytoskeletal dynamics [22]. In response to 
injurious or infectious stimuli, they also act as dam-
age-associated molecular pattern molecules, with in-
creased expression and release at sites of inflammation 
[23]. The most studied S100 proteins in JIA are S100A8 
(also known as myeloid-related protein [MRP] 8 and cal-
granulin A), S100A9 (also known as MRP 14 and cal-
granulin B), and S100A12 (also known as MRP 6 and cal-
granulin C). S100A8 and S100A9 often exist as a complex 
of S100A8 and S100A9, (also known as calprotectin, and 
S100A8–S100A9), which is the most prevalent form un-
der most physiological conditions. Increased levels of 
S100A8–S100A9 and S100A12 in the serum and synovial 
fluid were shown to correlate with disease activity in JIA, 
suggesting that these proteins may be promising markers 
for monitoring disease activity [24-26]. 
MMP-3 is an enzyme that in humans is involved in the 
breakdown of extracellular matrix, and may induce degra-
dation of cartilage and bone in arthritis [27]. Concentrations 
of MMP-3 in the serum were higher in children with ERA 
than in healthy subjects and were correlated with clinical 
parameters of disease activity [28,29]. Therefore, MMP-3 
is expected to serve as a useful biomarker for monitoring 
disease activity in JIA.
Biomarkers used to predict the disease course
RFs and anti-CCP antibodies are not only components 
of the classification criteria for JIA, but are also important 
predictors of disease prognosis. Older children with RF 
tend to have a longer disease duration, subcutaneous 
rheumatoid nodules or articular erosions, or a poorer 
functional class, which mimics adult RA [12,18]. In most 
studies, anti-CCP antibodies have been detected predom-
inantly in patients with RF-positive polyarticular JIA 
[17]. The prognostic value of anti-CCP antibodies in JIA 
is yet to be studied, but in small studies they seem to be 
associated with a worse prognosis [30,31].
MAS is an aggressive and life-threatening complication 
of systemic inflammatory disorders. MAS occurs most 
frequently with systemic JIA [32]. The hallmark clinical 
features of MAS include high fever, hepatosplenomegaly, 
lymphadenopathy, hemorrhagic manifestations, and en-
cephalopathy [33]. The characteristic laboratory features 
are pancytopenia, liver dysfunction, disseminated intra-
vascular coagulation, hypofibrinogenemia, hypoalbuminemia, 
hyperferritinemia, hypertriglyceridemia, increased levels 
of lactate dehydrogenase, soluble CD25, soluble CD163, 
and decreased ESR levels [33]. With the recognition that 
MAS is clinically similar to hemophagocytic lymphohis-
tiocytosis (HLH), some have applied the HLH-2004 diag-
nostic guidelines to the diagnosis of MAS (Table 4) [34]. 
However, the main shortcoming of using HLH-2004 
guidelines is that some individual criteria may not be met 
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for systemic JIA patients. Due to the remarkable in-
flammatory properties of systemic JIA, a relative decrease 
in leukocyte count, platelet count or fibrinogen level may 
be more useful for early diagnosis of systemic JIA than the 
absolute reduction required by the HLH-2004 standard. 
Therefore, the classification criteria of MAS complicating 
systemic JIA were developed in 2014, based on a combi-
nation of expert consensus, evidence from the medical lit-
erature, and analysis of patient data (Table 4) [34].
Biomarkers that predict response to therapy and 
risk for relapse
The S100 proteins are not only biomarkers for disease 
activity monitoring in JIA, but also serve as useful bio-
markers to predict the response to treatment or disease 
flares in JIA. High serum levels of S100A8–S100A9 pro-
teins before anti-rheumatic therapies were associated 
with good responses to methotrexate [35-37], and an-
ti-tumor necrosis factor (TNF) agents [36]. In contrast, 
the higher levels of S100A8–S100A9 in the serum during 
remission were associated with a risk of relapse after dis-
continuation of methotrexate, which supported the hy-
pothesis that the levels of these proteins in the serum 
could be useful parameters to inform the decision to dis-
continue treatment [37].
Similar to the findings for S100A8–S100A9, JIA patients 
with increased levels of serum S100A12 were also more 
likely to respond favorably to methotrexate or anti-TNF 
treatment. Increased levels of serum S100A12 during re-
mission were associated with an increased risk of disease 
flare [38-40]. Similar to non-systemic JIA, increased se-
rum levels of S100A8–S100A9 during clinical remission 
was also a useful biomarker to predict relapse after ther-
apy withdrawal in systemic JIA [25,35]. IL-18 and 
S100A8–S100A9 serum levels may be candidate bio-
markers for response to therapy in systemic JIA [41]. 
IL-18 serum levels increased in 4 out of 8 children who ex-
perienced failure in tapering of therapy and slightly in-
creased in only 1 out of 7 patients who experienced suc-
cessful tapering of therapy [42]. S100 proteins and IL-18 
are considered for useful markers for predicting treat-
ment response and relapse in systemic JIA and for the di-
agnosis of the JIA subtype.
CONCLUSION
Biomarkers serve as useful tools for the diagnosis of JIA 
subtypes, prediction of disease progression, and estab-
lishment of treatment strategies by assessing the re-
sponse to therapy and relapse risk. The current classi-
fication of JIA remains a challenging area, especially given 
the heterogeneous nature of the disease. Therefore, to 
achieve the best outcome, it is important to carefully se-
lect appropriate biomarkers based on the disease subtype. 
As the genetic and pathophysiological understanding of 
JIA improves, new classification systems will define ho-
mogeneous groups of children, each with a biologically 
distinct disease. The identification of new biomarkers 
with more effective diagnostic/prognostic value could 
help to achieve the ultimate goal of facilitating the im-
plementation of targeted therapies and tailored treat-
ment interventions and improving remission rates while 
minimizing disease damage. 
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